Table 1.
Information on the hospitalization of the patient and the course of the disease for 2019–2022.
| Periods of Examination | Sweat Conductivity, NaCl mmol/L | Weight, kg |
Clinical Features | FEV1 |
|---|---|---|---|---|
| August 2019 | 121 | 45 | Bronchopulmonary exacerbation (increased cough, purulent sputum, hemoptysis) | 2.38 L (76.3%) |
| Start tezacaftor/ivacaftor and ivacaftor 100/150 mg and 150 mg | ||||
| October 2019 | 114 | 46 | Examination before tezacaftor/ivacaftor and ivacaftor |
2.52 L (80.7%) |
| December 2019 | 108 | 44 | Control examination after 6 weeks of admission tezacaftor/ivacaftor and ivacaftor |
2.64 L (84.4%) |
| March 2020 | 123 | 46.5 | Bronchopulmonary exacerbation (fever, increased cough, hemoptysis) | 2.84 L (90.4%) |
| March–August 2020 Break from tezacaftor/ivacaftor and ivacaftor for 1.5 months; course resumed from 25 May 2020 to 28 August 2020 | ||||
| August 2020 |
119 | 48 | Pneumonia | 2.50 L (75%) |
| October 2020 | - | 46.5 | Respiratory viral infection | 2.91 L (87.3%) |
| September 2021 | - | 48 | Bronchopulmonary exacerbation (fever, increased cough) | 3.3 L (82%) |
| 30 November 2021 Started elexacaftor/tezacaftor/ivacaftor and ivacaftor at 100/50/75 mg and 150 mg (2 tablets in the morning, 1 tablet ivacaftor 150мг in the evening) | ||||
| January 2022 | - | 49 | COVID-19: fever of 39 °C for 3 days, headaches | - |
| February 2022 | 55 | 54 | Pneumonia, hemoptysis CRP—21.8 mg/L |
3.84 L (108%) |
| June 2022 | 66 | 55.6 | Planned hospitalization for intravenous therapy, CRP < 5 mg/L, ESR—norm | 3.7 L (104.3%) |